Quick Takeaways
- Polar Capital Holdings Plc filed SCHEDULE 13G/A for ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, par value $0.0001 (ARQT).
- Disclosed ownership: 5.6%.
- Date of event: 31 Mar 2025.
Polar Capital Holdings Plc - 31 Mar 2025 SCHEDULE 13G/A Report for ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, par value $0.0001 (ARQT)
- Filing Manager
- Polar Capital Holdings Plc
- Reporting Manager
- Polar Capital Holdings Plc
- Symbol
- ARQT
- Shares outstanding
- 118,698,673 shares
- Disclosed Ownership
- 6,706,475 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 10:13:25 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Polar Capital Holdings Plc disclosed 5.6% ownership in ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, par value $0.0001 (ARQT) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 10:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 5.6% | 6,706,475 | 6,706,475 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital LLP | 5.6% | 6,706,475 | 6,706,475 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital Funds PLC - Biotechnology Fund | 5.1% | 6,000,000 | 6,000,000 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer |